Treatment of HCV: approach to difficult cases (Q35960907)

11 August 2017

1 reference

title

Treatment of HCV: approach to difficult cases (English)

1 reference

11 August 2017

Schiff ER

1

1 reference

PubMed ID

15560064

11 August 2017

Tagle FM

series ordinal

2

1 reference

11 August 2017

1 November 1997

1 reference

11 August 2017

Clinics in liver disease

1 reference

11 August 2017

1

1 reference

11 August 2017

3

1 reference

11 August 2017

647-62, viii-ix

1 reference

Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV.

11 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Chronic hepatitis with combined features of autoimmune chronic hepatitis and chronic hepatitis C: favorable response to prednisone and azathioprine

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

N-acetyl cysteine enhances the response to interferon-alpha in chronic hepatitis C: a pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

High-dose interferon-alpha 2b for re-treatment of nonresponders or relapsing patients with chronic hepatitis C. A controlled randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Serum autoantibodies and the diagnosis of type-1 autoimmune hepatitis in Italy: a reappraisal at the light of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Superinfection with hepatitis C virus in patients with symptomatic chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. TriVeneto Viral Hepatitis Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Hepatitis C virus infection as a determinant of behavior in type 1 autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Hepatitis C virus infection among health care workers

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Hepatitis C and Hepatocellular Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Antibody to Hepatitis C Virus among Cardiac Surgery Patients, Homosexual Men, and Intravenous Drug Users in Baltimore, Maryland

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian Seroconversion Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Transmission of hepatitis C virus by a cardiac surgeon.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

High Rate of Infectivity and Liver Disease in Blood Donors with Antibodies to Hepatitis C Virus

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

The significance of antibody to hepatitis C virus in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Therapy of Hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Prevalence of hepatitis C infection in health care workers affiliated with a liver transplant center

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Lymphocytic sialadenitis of Sjögren's syndrome associated with chronic hepatitis C virus liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Hepatitis C virus associated primary hepatocellular carcinoma in a noncirrhotic liver

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Glove perforation during sternotomy closure

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Membranoproliferative glomerulonephritis associated with hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Le Groupe Français pour l'Etude du Traitement des Hépatites Chroniques NANB/C

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Simultaneous acute infections with hepatitis non-A, non-B, and B viruses

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Displacement of hepatitis B virus by hepatitis C virus as the cause of continuing chronic hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Use of confirmatory assays for diagnosis of hepatitis C viral infection in patients with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Retreatment with recombinant interferon-alpha in patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Liver histology in anti-HCV-positive persons with normal or minimally elevated aminotransferases.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Hepatitis C virus infection in patients infected with the human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Psychiatric complications of long-term interferon alfa therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Coinfection of hepatitis C virus in patients with chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Hepatitis C from a needlestick injury

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Hepatitis C in human immunodeficiency virus-coinfected patients: increased variability in the hypervariable envelope coding domain

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Long-term follow-up of patients with chronic hepatitis C treated with α-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Interferon-induced chronic active hepatitis?

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

From the Center for Disease Control: comparative risk of hepatitis B amono physicians and dentists

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Efficacy and safety of alpha-interferon treatment for chronic hepatitis C in HIV-infected patients. HIV-Hepatitis Spanish Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Occupational risk of hepatitis C infections among general dentists and oral surgeons in North America

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Interferon for non-A, non-B chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Rapid decline of CD4+ cells after IFN alpha treatment in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Zidovudine therapy associated with remission of chronic active hepatitis C in HIV-1 carriers

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Clinical significance of anti-IFN-alpha antibody titres during interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970327-5

7 January 2021

10.1016/S1089-3261(05)70327-5

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

15560064